Immune Checkpoint Inhibitors as Switch or Continuous Maintenance Therapy in Solid Tumors: Rationale and Current State

home / between-the-lines / immune-checkpoint-inhibitors-as-switch-or-continuation-maintenance-therapy-in-solid-tumors-ratio

Drs. Gupta and Brown discuss a recently published paper by Grivas et al. (2019) on the use of checkpoint inhibitors for maintenance therapy to prolong the benefits of frontline therapy while minimizing toxicity in solid tumors.